Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.32B |
| 2 |
AstraZeneca
AZN
|
+$733M |
| 3 |
Microsoft
MSFT
|
+$728M |
| 4 |
Cadence Design Systems
CDNS
|
+$720M |
| 5 |
Moody's
MCO
|
+$359M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$1.43B |
| 2 |
Estee Lauder
EL
|
+$872M |
| 3 |
Eli Lilly
LLY
|
+$626M |
| 4 |
Netflix
NFLX
|
+$521M |
| 5 |
UnitedHealth
UNH
|
+$466M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.19% |
| 2 | Consumer Discretionary | 19.62% |
| 3 | Healthcare | 16.16% |
| 4 | Financials | 9.12% |
| 5 | Communication Services | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Steel Dynamics
STLD
$37.5B
| $8.91M | 0.01% |
78,809
-18,669
| -19% | -$2.17M |
|
|
APTV.PRA
402
DELISTED
Aptiv PLC 5.50% Series A Mandatory Convertible Preferred Shares
APTV.PRA
| $8.87M | 0.01% |
72,300
| – | – |
|
|
IMGN
403
DELISTED
Immunogen Inc
IMGN
| $8.87M | 0.01% |
2,308,596
-6,831,763
| -75% | -$29.1M |
|
404
iShares Russell 1000 Growth ETF
IWF
$127B
| $8.86M | 0.01% |
145,036
-489,944
| -77% | -$28.2M |
|
|
GTLS
405
DELISTED
Chart Industries
GTLS
| $8.6M | 0.01% |
68,609
+42
| +0.1% | +$5.41K |
|
406
Monolithic Power Systems
MPWR
$66.8B
| $8.58M | 0.01% |
+17,145
| New | +$7.88M |
|
407
Republic Services
RSG
$64.5B
| $8.52M | 0.01% |
63,016
-120,636
| -66% | -$15.4M |
|
408
Expro Ltd
XPRO
$1.91B
| $8.52M | 0.01% |
+464,074
| New | +$9.11M |
|
409
Moelis & Co
MC
$4.98B
| $8.39M | 0.01% |
218,207
-28,324
| -11% | -$1.22M |
|
|
AAT
410
American Assets Trust
AAT
$1.38B
| $8.3M | 0.01% |
446,652
-176,394
| -28% | -$4.3M |
|
411
Kinder Morgan
KMI
$69.7B
| $8.25M | 0.01% |
471,063
| – | – |
|
|
HSKA
412
DELISTED
Heska Corp
HSKA
| $8.16M | 0.01% |
+83,548
| New | +$7.01M |
|
413
Madrigal Pharmaceuticals
MDGL
$11.8B
| $7.99M | 0.01% |
32,987
-25,969
| -44% | -$7.08M |
|
414
Weatherford International
WFRD
$6.38B
| $7.69M | 0.01% |
+129,607
| New | +$7.59M |
|
|
NVRO
415
DELISTED
NEVRO CORP.
NVRO
| $7.54M | 0.01% |
208,615
+4,265
| +2% | +$150K |
|
416
Transocean
RIG
$5.71B
| $7.48M | 0.01% |
+1,176,356
| New | +$7.55M |
|
|
CTLT
417
DELISTED
CATALENT, INC.
CTLT
| $7.36M | 0.01% |
112,070
-189,783
| -63% | -$11.7M |
|
418
Nutrien
NTR
$32B
| $7.36M | 0.01% |
99,683
-408
| -0.4% | -$31.5K |
|
419
TFI International
TFII
$11.3B
| $7.23M | 0.01% |
60,596
-5,671
| -9% | -$661K |
|
420
Rush Enterprises Class A
RUSHA
$6.2B
| $7.18M | 0.01% |
197,315
-1,464
| -0.7% | -$53K |
|
421
TC Energy
TRP
$66.6B
| $7.13M | 0.01% |
183,330
-50,890
| -22% | -$2.07M |
|
422
KKR & Co
KKR
$92.8B
| $7.06M | 0.01% |
134,456
-6,332,608
| -98% | -$340M |
|
423
Cabaletta Bio
CABA
$450M
| $6.46M | 0.01% |
+780,564
| New | +$7.31M |
|
424
Nordson
NDSN
$17.2B
| $6.44M | 0.01% |
28,990
-30,446
| -51% | -$6.97M |
|
|
MAG
425
DELISTED
MAG Silver
MAG
| $6.25M | 0.01% |
494,577
-1,661
| -0.3% | -$22.3K |
|
Similar funds
Jennison Associates's Q1 2023 Portfolio in Review
As of Q1 2023, Jennison Associates held 644 positions worth $109B, up 10% from $98.7B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Jennison Associates withdrew a net $3.94B in Q1 2023, closing 63 positions and reducing 280 holdings. Its most notable exit was Alcon, an estimated $1.43B position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Advanced Micro Devices worth $1.59B.
- Jennison Associates's largest Q1 2023 buy was Advanced Micro Devices: 16,272,765 shares worth $1.59B.
- Jennison Associates added most to AstraZeneca in Q1 2023, an estimated $733M increase.
- Jennison Associates's biggest Q1 2023 reduction was Estee Lauder, cutting an estimated $872M.
- Jennison Associates fully exited Alcon in Q1 2023, selling an estimated $1.43B.
- Jennison Associates's ten largest holdings make up 39% of its $109B portfolio in Q1 2023.
- Jennison Associates opened 73 new positions and closed 63 in Q1 2023.
- Jennison Associates's portfolio value rose 10% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.